// App-Quantinova.ai

OC 27.2 : Clinical Outcomes Following Prophylaxis With Octocog Alfa in Patients With Moderate Hemophilia A: 8-Year Interim Read-out of the Real-world AHEAD International Study

Researchers

Presenter

  • M. Ozelo

Principal Investigators

  • C. Hermans

  • K. Khair

  • B. Guillet

  • J. Gu

  • L. Tang

  • M. Carcao

Medical Centers

  • Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Sao Paulo, Brazil

  • Saint-Luc University Hospital, Université Catholique de Louvain, Louvain, Vlaams-Brabant, Belgium

  • Great Ormond Street Hospital for Children, London, England, United Kingdom

  • CRC-MHC, CHU de Rennes – Hôpital Pontchaillou, Rennes, France, Rennes, Bretagne, France

  • Takeda Development Center Americas, Inc., Cambridge, MA, Cambridge, Massachusetts, United States

  • Takeda Pharmaceutical International AG, Zürich, Switzerland

  • Division of Haematology/Oncology, Department of Paediatrics and Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

Locations

  • Brazil

  • Belgium

  • United Kingdom

  • France

  • United States

  • Switzerland

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • Antihemophilic factor recombinant

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02078427

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved